《世界卫生组织乳腺肿瘤分类（第4版）概述》，重点关注第3版以来的问题及更新内容。
A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition.
作者信息
Sinn Hans-Peter, Kreipe Hans
机构信息
Sektion für Gynäkologische Pathologie, Pathologisches Institut, Ruprecht-Karls-Universität Heidelberg, Germany.
Institut für Pathologie, Medizinische Hochschule Hannover, Germany.
出版信息
Breast Care (Basel). 2013 May;8(2):149-54. doi: 10.1159/000350774.
Abstract
The WHO Classification of Tumors of the Breast, 4th edition, is an update to the 3rd edition that was published in 2003, and covers all neoplastic and preneoplastic lesions of the breast. Changes to the 4th edition include new aspects and changes to the terminology that reflect our present-day knowledge of these lesions. Definitions for histopathological diagnosis are complemented by a description of clinical features, epidemiology, macroscopy, genetics, and prognostic and predictive features. In this review of the WHO classification, we have focused on invasive carcinomas, precursor lesions, and some benign epithelial proliferations.
摘要
《世界卫生组织乳腺肿瘤分类》第4版是2003年出版的第3版的更新版本，涵盖了乳腺的所有肿瘤性和肿瘤前病变。第4版的变化包括反映我们目前对这些病变认识的新内容和术语变化。组织病理学诊断的定义辅以临床特征、流行病学、大体检查、遗传学以及预后和预测特征的描述。在本次对世界卫生组织分类的综述中，我们重点关注浸润性癌、前驱病变和一些良性上皮增生。
相似文献
1
A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition.
Breast Care (Basel). 2013 May;8(2):149-54. doi: 10.1159/000350774.
2
Myoepithelial and epithelial-myoepithelial, mesenchymal and fibroepithelial breast lesions: updates from the WHO Classification of Tumours of the Breast 2012.
J Clin Pathol. 2013 Jun;66(6):465-70. doi: 10.1136/jclinpath-2012-201078. Epub 2013 Mar 26.
3
Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition.
Arch Pathol Lab Med. 2008 Jun;132(6):993-1007. doi: 10.5858/2008-132-993-SNUARO.
5
Recent Advances in the Classification of Gynecological Tract Tumors: Updates From the 5th Edition of the World Health Organization "Blue Book".
Arch Pathol Lab Med. 2023 Oct 1;147(10):1204-1216. doi: 10.5858/arpa.2022-0166-RA.
6
Recent Advances in Digestive Tract Tumors: Updates From the 5th Edition of the World Health Organization "Blue Book".
Arch Pathol Lab Med. 2021 May 1;145(5):607-626. doi: 10.5858/arpa.2020-0047-RA.
7
[Invasive breast cancer: the current WHO classification].
Pathologe. 2014 Feb;35(1):7-17. doi: 10.1007/s00292-013-1841-7.
8
Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Odontogenic and Maxillofacial Bone Tumors.
Head Neck Pathol. 2017 Mar;11(1):68-77. doi: 10.1007/s12105-017-0794-1. Epub 2017 Feb 28.
9
Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis.
Hepatol Res. 2002 Dec;24(4):395-403. doi: 10.1016/s1386-6346(02)00144-4.
10
Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: What is New in the 2017 WHO Blue Book for Tumours of the Hypopharynx, Larynx, Trachea and Parapharyngeal Space.
Head Neck Pathol. 2017 Mar;11(1):23-32. doi: 10.1007/s12105-017-0788-z. Epub 2017 Feb 28.
引用本文的文献
1
Genomic Predictive Biomarkers in Breast Cancer: The and .
Int J Mol Sci. 2025 Jul 28;26(15):7300. doi: 10.3390/ijms26157300.
2
The association between body mass index and neoadjuvant chemotherapy response in patients with breast cancer.
Breast Cancer Res. 2025 Jul 11;27(1):130. doi: 10.1186/s13058-025-02083-w.
3
Real-World, National Study of Palbociclib in HR+/HER2- Metastatic Breast Cancer: A 2.5-Year Follow-Up PALBO01/2021.
Diagnostics (Basel). 2025 May 5;15(9):1173. doi: 10.3390/diagnostics15091173.
4
HbA levels and breast cancer prognosis in women without diabetes.
BMC Cancer. 2025 Apr 28;25(1):790. doi: 10.1186/s12885-025-14121-z.
5
Artificial Intelligence in Histologic Diagnosis of Ductal Carcinoma In Situ.
Mayo Clin Proc Digit Health. 2023 Jun 25;1(3):267-275. doi: 10.1016/j.mcpdig.2023.05.008. eCollection 2023 Sep.
6
Breast cancer treatment modalities, treatment delays, and survival in Brunei Darussalam.
BMC Cancer. 2025 Mar 20;25(1):510. doi: 10.1186/s12885-025-13861-2.
7
PRR13 expression as a prognostic biomarker in breast cancer: correlations with immune infiltration and clinical outcomes.
Front Mol Biosci. 2025 Mar 3;12:1518031. doi: 10.3389/fmolb.2025.1518031. eCollection 2025.
8
Pathogenic Germline Variants in Patients With Metaplastic Breast Cancer.
JAMA Netw Open. 2025 Feb 3;8(2):e2460312. doi: 10.1001/jamanetworkopen.2024.60312.
9
Mastectomy, HER2 Receptor Positivity, NPI, Late Stage and Luminal B-Type Tumor as Poor Prognostic Factors in Geriatric Patients with Breast Cancer.
Diagnostics (Basel). 2024 Dec 25;15(1):13. doi: 10.3390/diagnostics15010013.
10
Secretory Breast Carcinoma: A Rare Breast Cancer With an Excellent Behavior.
Cureus. 2024 Nov 9;16(11):e73312. doi: 10.7759/cureus.73312. eCollection 2024 Nov.
本文引用的文献
1
Metaplastic breast cancer: clinicopathological features and its prognosis.
J Clin Pathol. 2012 May;65(5):441-6. doi: 10.1136/jclinpath-2011-200586. Epub 2012 Mar 12.
2
Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers.
J Pathol. 2012 Jan;226(1):84-96. doi: 10.1002/path.2974. Epub 2011 Oct 20.
3
A clinically relevant gene signature in triple negative and basal-like breast cancer.
Breast Cancer Res. 2011 Oct 6;13(5):R97. doi: 10.1186/bcr3035.
4
Concordance in histological and biological parameters between first and second primary breast cancers.
Cancer. 2011 Mar 1;117(5):907-15. doi: 10.1002/cncr.25587. Epub 2010 Oct 13.
5
Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type.
J Pathol. 2010 Nov;222(3):282-98. doi: 10.1002/path.2763.
6
Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma.
Cancer. 2010 Oct 1;116(19):4463-73. doi: 10.1002/cncr.25352.
7
Breast core needle biopsy: issues and controversies.
Mod Pathol. 2010 May;23 Suppl 2:S36-45. doi: 10.1038/modpathol.2010.34.
8
Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential.
Semin Diagn Pathol. 2010 Feb;27(1):77-90. doi: 10.1053/j.semdp.2009.12.007.
9
Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.
Mod Pathol. 2010 Feb;23(2):205-12. doi: 10.1038/modpathol.2009.159. Epub 2009 Nov 6.
10
The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast.
Eur J Cancer. 2009 Jul;45(10):1780-7. doi: 10.1016/j.ejca.2009.02.014. Epub 2009 Mar 14.
Zotero 插件